{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:07:21Z","timestamp":1791220041614,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,9,17]],"date-time":"2008-09-17T00:00:00Z","timestamp":1221609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00403-008-0895-5","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T05:12:39Z","timestamp":1221541959000},"page":"99-105","source":"Crossref","is-referenced-by-count":216,"title":["Drug-induced lupus erythematosus"],"prefix":"10.1007","volume":"301","author":[{"given":"Camilla Dalle","family":"Vedove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Del Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Schena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,17]]},"reference":[{"key":"895_CR1","first-page":"756","volume":"22","author":"Y Allanore","year":"2004","unstructured":"Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A (2004) Induction of autoantibody in refractory rheumatoid arthritis patients treated by infliximab. Clin Exp Rheumatol 22:756\u2013758","journal-title":"Clin Exp Rheumatol"},{"key":"895_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clindermatol.2003.12.023","volume":"22","author":"D Antonov","year":"2004","unstructured":"Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N (2004) Drug-induced lupus erythematosus. Clin Dermatol 22:157\u2013166. doi: 10.1016\/j.clindermatol.2003.12.023","journal-title":"Clin Dermatol"},{"key":"895_CR3","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","volume":"8","author":"F Atzeni","year":"2006","unstructured":"Atzeni F, Sarzi-Puttini P, Dell\u2019Acqua D, De Portu S, Cecchini G, Cruini C et al (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3. doi: 10.1186\/ar1851","journal-title":"Arthritis Res Ther"},{"key":"895_CR4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","volume":"1108","author":"AT Borchers","year":"2007","unstructured":"Borchers AT, Keen CL, Gershwin ME (2007) Drug-induced lupus. Ann N Y Acad Sci 1108:166\u2013182. doi: 10.1196\/annals.1422.019","journal-title":"Ann N Y Acad Sci"},{"key":"895_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0b013e328010c547","volume":"19","author":"FA Borg","year":"2007","unstructured":"Borg FA, Isenberg DA (2007) Syndromes and complications of interferon therapy. Curr Opin Rheumatol 19:61\u201366. doi: 10.1097\/BOR.0b013e328010c547","journal-title":"Curr Opin Rheumatol"},{"key":"895_CR6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00296-004-0542-1","volume":"26","author":"P Caramaschi","year":"2006","unstructured":"Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A et al (2006) Anti-TNF\u03b1 therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26:209\u2013214. doi: 10.1007\/s00296-004-0542-1","journal-title":"Rheumatol Int"},{"key":"895_CR7","doi-asserted-by":"crossref","unstructured":"Costa MF, Said NR, Zimmermann B (2007) Drug-induced lupus due to anti-tumor necrosis factor \u03b1 agents. Semin Arthritis Rheum. Epub ahead of print","DOI":"10.1016\/j.semarthrit.2007.08.003"},{"key":"895_CR8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","volume":"15","author":"N Danchenko","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308\u2013318. doi: 10.1191\/0961203306lu2305xx","journal-title":"Lupus"},{"key":"895_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","volume":"255","author":"F D\u2019Auria","year":"2004","unstructured":"D\u2019Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi A et al (2004) Accumulation of plasma nucleosomes upon treatment with anti-tumor necrosis factor-alpha antibodies. J Intern Med 255:409\u2013418. doi: 10.1111\/j.1365-2796.2003.01298.x","journal-title":"J Intern Med"},{"key":"895_CR10","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M Bant De","year":"2005","unstructured":"De Bant M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545\u2013R551. doi: 10.1186\/ar1715","journal-title":"Arthritis Res Ther"},{"key":"895_CR11","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","volume":"52","author":"L Rycke De","year":"2005","unstructured":"De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-dsDNA antibodies as main antinuclear reactivity: biological and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192\u20132201. doi: 10.1002\/art.21190","journal-title":"Arthritis Rheum"},{"key":"895_CR12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","volume":"20","author":"SB Desai","year":"2006","unstructured":"Desai SB, Furst DE (2006) Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 20:757\u2013790. doi: 10.1016\/j.berh.2006.06.002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"895_CR13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64:403\u2013407. doi: 10.1136\/ard.2004.024182","journal-title":"Ann Rheum Dis"},{"key":"895_CR14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","volume":"12","author":"F Fantuzzi","year":"2008","unstructured":"Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G (2008) Targeting TNF-\u03b1 in psoriasis. Exp Opin Ther Targets 12:1085\u20131096","journal-title":"Exp Opin Ther Targets"},{"key":"895_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.61.4.358","volume":"61","author":"G Ferraccioli","year":"2002","unstructured":"Ferraccioli G, Mecchia F, Di Poi E, Fabris M (2002) Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61:358\u2013361. doi: 10.1136\/ard.61.4.358","journal-title":"Ann Rheum Dis"},{"key":"895_CR16","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","volume":"6","author":"C Ferraro-Peyret","year":"2004","unstructured":"Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing apondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535\u2013R543. doi: 10.1186\/ar1440","journal-title":"Arthritis Res Ther"},{"key":"895_CR17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.autrev.2006.12.002","volume":"6","author":"P Gisondi","year":"2007","unstructured":"Gisondi P, Girolomoni G (2007) Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 6:515\u2013519. doi: 10.1016\/j.autrev.2006.12.002","journal-title":"Autoimmun Rev"},{"key":"895_CR18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/120347540300700310","volume":"7","author":"E Gubinelli","year":"2003","unstructured":"Gubinelli E, Cocuroccia B, Girolomoni G (2003) Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg 7:243\u2013246. doi: 10.1007\/s10227-002-0122-5","journal-title":"J Cutan Med Surg"},{"key":"895_CR19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. Lancet 359:1541\u20131549. doi: 10.1016\/S0140-6736(02)08512-4","journal-title":"Lancet"},{"key":"895_CR20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/32.2.110","volume":"32","author":"ND Hopkinson","year":"1993","unstructured":"Hopkinson ND, Doherty M, Powell RJ (1993) The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK 1989\u20131990. Br J Rheumatol 32:110\u2013115. doi: 10.1093\/rheumatology\/32.2.110","journal-title":"Br J Rheumatol"},{"key":"895_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/CRIAI:25:1:3","volume":"25","author":"S Jimenez","year":"2003","unstructured":"Jimenez S, Cervera R, Font J, Ingelmo M (2003) The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 25:3\u201312. doi: 10.1385\/CRIAI:25:1:3","journal-title":"Clin Rev Allergy Immunol"},{"key":"895_CR22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.1780380415","volume":"38","author":"AE Johnson","year":"1995","unstructured":"Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38:551\u2013558. doi: 10.1002\/art.1780380415","journal-title":"Arthritis Rheum"},{"issue":"Supplement","key":"895_CR23","first-page":"S543","volume":"52","author":"L Klareskog","year":"2005","unstructured":"Klareskog L, Wajdula J, Yeh P (2005) Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis. Arthritis Rheum 52(Supplement):S543 abstract 881","journal-title":"Arthritis Rheum"},{"key":"895_CR24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1191\/0961203303lu469xx","volume":"12","author":"P Lopez","year":"2003","unstructured":"Lopez P, Mozo Gutierrez C, Suarez A (2003) Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 12:860\u2013865. doi: 10.1191\/0961203303lu469xx","journal-title":"Lupus"},{"key":"895_CR25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2133.2007.08056.x","volume":"157","author":"DJ Margolis","year":"2007","unstructured":"Margolis DJ, Hoffstad O, Bilker W (2007) Association or lack association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 157:540\u2013546. doi: 10.1111\/j.1365-2133.2007.08056.x","journal-title":"Br J Dermatol"},{"key":"895_CR26","first-page":"740","volume":"32","author":"A Mor","year":"2005","unstructured":"Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM (2005) Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 32:740\u2013743","journal-title":"J Rheumatol"},{"key":"895_CR27","doi-asserted-by":"crossref","unstructured":"Mor A, Pillinger MH, Wortmann RL, Mitnick HJ (2007) Drug-induced arthritic and connective tissue disorders. Sem Arthritis Rheum. Epub ahead of print","DOI":"10.1016\/j.semarthrit.2007.10.001"},{"key":"895_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","volume":"21","author":"B Noel","year":"2007","unstructured":"Noel B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21:17\u201324. doi: 10.1111\/j.1468-3083.2006.01838.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"895_CR29","doi-asserted-by":"crossref","unstructured":"Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G (2008) Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. Epub ahead of print","DOI":"10.1016\/j.jaad.2008.03.009"},{"key":"895_CR30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","volume":"156","author":"N Poulalhon","year":"2007","unstructured":"Poulalhon N, Begon E, Lebb\u00e9 C, Liot\u00e9 F, Lahfa M, Bengoufa D et al (2007) A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 156:329\u2013336. doi: 10.1111\/j.1365-2133.2006.07639.x","journal-title":"Br J Dermatol"},{"key":"895_CR31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","volume":"358","author":"A Rahaman","year":"2008","unstructured":"Rahaman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929\u2013939. doi: 10.1056\/NEJMra071297","journal-title":"N Engl J Med"},{"key":"895_CR32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242\u2013251. doi: 10.1097\/MD.0b013e3181441a68","journal-title":"Medicine (Baltimore)"},{"key":"895_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tox.2004.12.025","volume":"209","author":"RL Rubin","year":"2005","unstructured":"Rubin RL (2005) Drug-induced lupus. Toxicology 209:135\u2013147. doi: 10.1016\/j.tox.2004.12.025","journal-title":"Toxicology"},{"key":"895_CR34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbspin.2004.03.003","volume":"72","author":"J Sellam","year":"2005","unstructured":"Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A (2005) Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and etanercept. Joint Bone Spine 72:48\u201352. doi: 10.1016\/j.jbspin.2004.03.003","journal-title":"Joint Bone Spine"},{"key":"895_CR35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.22683","volume":"57","author":"EC Somers","year":"2007","unstructured":"Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ (2007) Incidence of systemic lupus erythematosus in the United Kingdom, 1990\u20131999. Arthritis Rheum 57:612\u2013618. doi: 10.1002\/art.22683","journal-title":"Arthritis Rheum"},{"key":"895_CR36","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"MB Stokes","year":"2005","unstructured":"Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufmen D (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400\u20131406. doi: 10.1093\/ndt\/gfh832","journal-title":"Nephrol Dial Transplant"},{"key":"895_CR37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archinte.159.5.493","volume":"159","author":"MC Sturkenboom","year":"1999","unstructured":"Sturkenboom MC, Meier CR, Jick H, Stricker B (1999) Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 159:493\u2013497. doi: 10.1001\/archinte.159.5.493","journal-title":"Arch Intern Med"},{"key":"895_CR38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/3-540-26581-3_9","volume-title":"Cutaneous lupus erythematosus","author":"J Uetrecht","year":"2005","unstructured":"Uetrecht J (2005) Drug-induced lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin, pp 117\u2013132"},{"key":"895_CR39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/kel227","volume":"45","author":"AVAM van Rijthoven","year":"2006","unstructured":"van Rijthoven AVAM, Bijlsma JWJ, Canninga- Van Dijk M, Derksen RHWM, van Roon JAG (2006) Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology 45:1317\u20131319. doi: 10.1093\/rheumatology\/kel227","journal-title":"Rheumatology"},{"key":"895_CR40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0961203306070000","volume":"15","author":"S Vasoo","year":"2006","unstructured":"Vasoo S (2006) Drug-induced lupus: an update. Lupus 15:757\u2013761. doi: 10.1177\/0961203306070000","journal-title":"Lupus"},{"key":"895_CR41","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","volume":"167","author":"CS Via","year":"2001","unstructured":"Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD (2001) In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167:6821\u20136826","journal-title":"J Immunol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-008-0895-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-008-0895-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-008-0895-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:37:40Z","timestamp":1559050660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-008-0895-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s00403-008-0895-5","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,17]]}}}